INDEX

access to medicine. See also legal and policy constructs
through advance market commitments, 342
aging populations and, 3, 4–6
through alliances and collaborations, 432–435
under Bali Concord III, 425–426
through biologics, 405–408
through biosimilar products, 405–408
in BRICS nations, 430–432
business model changes and, 48–55
businesses’ role and, 352–353
capacity-building as factor in, 435–436
civil society’s role in, 66
competition law and, xxii
data exclusivity protection and, 190–191
data protection and, 353–366
through data sharing and, 354–358
domestic healthcare policies and, 38–41
end user interests and, 64
in EU, R&D collaborations for, 348
FTAs and, 55–56, 72–77, 137–156, 157–158
funding models for, 348–352
future challenges for, 436–438
through GIIN, 348
global public health and, 29–32
governmental influences on, 418–422
governments’ role and, 342–344
through halal pharmaceuticals, 410–411
through health funds and prizes, 339
healthcare costs containment and, 65
impact investing and, 348–350
infrastructure and, 9
innovative-incentive approach to patents and, 67–68
innovator interests and, 64–65
IPRs and, 338–339
legal education as factor in, 435–436
legal policies for, 26–27
marketing approval costs reduction for, 424
MPP and, 339, 340–342, 411
multilateral trade and treaties and, 389–404
new incentives for, 404–405
new paradigms and strategies for, 334–337
through non-adversarial problem-solving, 434–435
non-profit organizations as influence on, 66
non-treaty initiatives for, 339–342
Novartis initiatives, 404
through patent law, strengthening of, 418–420
patent law and, 68–72
through patentability standards, 418–420
through personalized medicines, 408
pharmaceutical industry and, 352–353, 411–418
code of conduct guidelines for, 413–414
corruption in supply chains as influence on, 420–422
patents for, 68–72
regulation of, 62–66
soft rules for, 412–418
through pharmaceutical initiatives, 422–430
access to medicine (cont.)
pharmaceutical patents and, 68–72
PPPs for, 344–348
procurement agreements and, 88–90
regional healthcare priorities and, 32–41
through regional integration, 422–430
role of international organizations in, 27–29
scientific advances and, 26–27
through SIBs, 348–349
in Singapore, ecosystem for, 345–347
social policy strategies for, 26–27
sovereign wealth funds and, 415–416, 417
state interests and, 65
through traditional medicines, 408–409
treaty-based approaches to, 366–377
TRIPS and, 24–26
in U.S., R&D collaborations for, 348
through voluntary licensing, 433
through voluntary licensing arrangements, 340–342
whole-of-government approach to, 373–376

Access to Medicines Index, 50, 411–412
active pharmaceutical ingredients (APIs), 17, 97
advance market commitments, 342
AEC. See ASEAN Economic Community
AFTA. See ASEAN Free Trade Area
aging populations in Asia, 3, 4–6
life expectancy and, 5
in Singapore, 3, 4–6
ALRC. See Australian Law Reform Commission
anti-competition
compulsory licensing as remedy against, 259–260
in FTAs, provisions for, 287
in Singapore, 329–330
in TRIPS, 259–260
Antimonopoly Law, 322–323
anti-retroviral (ARV) drugs, 16

ASEAN and, access strategies of, 36–37
competition law and, 299
in South Africa, 299
anti-trust law, 289–290. See also competition law
APIs. See active pharmaceutical ingredients
approval systems, for drugs and medicines
in ASEAN countries, 139
length of time in, 96–97
in non-ASEAN countries, 140
patent linkage and, 137–143
ARV drugs. See anti-retroviral drugs
ASEAN. See Association of Southeast Asian Nations
ASEAN Economic Community (AEC), 2
ASEAN Free Trade Area (AFTA), 2
Asia. See also medicines, in Asia; specific countries
aging populations in, 3, 4–6
biosimilar products in, 406–407
biotechnology patents in, 117–127
Bolar exception in, 234–238
cancer incidences in, 8
chronic disease in, 7–8
communicable diseases in, 6–7
competition law in, 306–334
compulsory licensing in, 244, 254–260, 396–397
data exclusivity protection in, 146–156
data exclusivity protection throughout, 188–191
economic integration activities in, 22–23
economic reform in, 41–44
economic treaty exceptions and examples, 226
FTAs in, xxi, 2–3, 55–56, 167–168, 223
data exclusivity protections in, 188–191
patentability provisions in, 173–174
global pharmaceutical industry and, 48–55
INDEX 441

globalization as economic influence on, 1–3
health care challenges in, 4–6
health care costs in, 3, 12
Hepatitis C in, 7
HIV/AIDS in, 6–7
IPRs in, 41–44
ISDS system in, 202–203
life expectancy in, 5
malaria in, 7
national health expenditures throughout, 9–16
patent term extensions in, 157–158, 161–162
patentability of biotechnology in, 108–109, 117–127
pay-for-delay agreements in, 297–298
pharmaceutical expenses in, 9–11
pharmaceutical industry in, 48–55
anticompetitive conduct and, 326–330
for ASEAN, 307–316, 325–326
competition law and, 306–334
compulsory licensing and, 326–330
corruption in, 88–90
counterfeit pharmaceuticals and, 97–99
drug price-control systems for, 90–94
generic substitution policies, 95
GST and, 85–88
marketing approval time in, 96–97
national pricing for, 85–88, 90–94
GST for, 85–88
patent linkage and, 331–332
procurement agreements in, 88–90
tariffs for, 83–84, 85
taxes and charges for, 85–88
user attitudes within, 96
poverty in, 8–9
public use licensing in, 396–397
R&D in, 13–15
TIFA and, 2–3
TPP Agreement and, 23
TRIPS and, xxi
tuberculosis in, 7
U.S. economic interest in, 2–3
Association for Molecular Pathology et al v Myriad Genetics Inc et al, 110–111
Association of Southeast Asian Nations (ASEAN), See also specific member nations
access to medicine influenced by, xxii, 32–41, 423–424, 425–426, 427–428
AEC, 2
AFTA, 2
ARV access and, strategies for, 36–37
Bali Concord III, 425–426
Bali Concord III and, 103
barriers, 423–424
data exclusivity protection for, 148–149
data sharing and, regional integration through, 428–429
domestic health policies and trade in medicine, 38–41
exhaustion of patent rights in, 161–162
FTAs and, 2–3
halal pharmaceuticals in, 410–411
HIV/AIDS integration strategies, 425–426
IPRs and, strategies for, 36, 43–44
ISDS claims against, 212, 213
junctures of opportunity for, 426–427
legal and policy constructs and, 103
marketing approval cost reductions in, 424
patent term extensions for, 157, 161–162
pharmaceutical approval systems in, 139
pharmaceutical industry and generic substitution policies for, 95
GST for, 85–88
national pricing for, 85–88, 90–94
tariffs for, 83–84, 85
taxes and charges for, 85–88
pharmaceutical production and, 18–21
Index

Association of Southeast Asian (cont.)
public health and, 427–428
RCEP and, 3
regional healthcare systems and, 32–41
TIFA and, 2–3
AstraZeneca AB v Ranbaxy (Malaysia) Sdn Bhd, 143
AstraZeneca AB (SE) v Sanoﬁ-Aventis Singapore Pte LTD, 141–143
AstraZeneca v Commission, 295–296
Australia
ALRC in, 301
BRCA litigation, 111–113
competition law in, 300–301
ISDS system in, 203, 278
patent law in, 56–57
patentability in, 111–113
Australia Patents Act, 111–113
Australian Law Reform Commission (ALRC), 301
Bali Concord III, 425–426
Bali Concord III, 103
Bayer Corporation v NATCO Pharma Ltd. in, 246–248
Bercero, Ignacio Garcia, 216–217
Bilateral Investment Promotion and Protection Agreement (BIPA), India, 206, 278–279
bilateral investment treaties (BITs), 26
Bilateral Trade Agreement (BTA), U.S. and Vietnam, 257
Biogen Inc v Medeva plc, 104–105
biologics, 405–408
biosimilar products, 405–408
biotechnology patents, 105. See also patentability
approval systems for, 137–143
in Asia, 117–127
in China, 125
data exclusivity protection for,
143–156
development of, 106–117
divergent approaches to, 117–127
evergreening approach to, 127
in India, 125–126
in Indonesia, 124

in Korea, 126–127
in Malaysia, 123–124
for new and secondary uses of compounds, 127–137
new uses of, 127–137
patent linkage as factor for, 137–143
in the Philippines, 124
in Singapore, 118–123
term extensions for, 156–158
in Thailand, 124
in Vietnam, 125
BIPA. See Bilateral Investment Promotion and Protection Agreement
BITs. See bilateral investment treaties
blockbuster drugs, 48–49
expiration of patents for, 49
Bolar exception, in TRIPS, 59, 229–238
in Asia, 234–238
in Canada, 230–231
in EU, 233
in R&D, 234–238
Roche Products v Bolar Pharmaceutical Co and, 229–230, 231
brand-name medicines, 16
Brazil
compulsory licensing in, 245–246
non-working patents in, 245–246
TRIPS Agreement and, 165
Brenner v Manson, 70
BRICS nations, public health in,
430–432. See also Brazil; China; India; South Africa
Brunei Darussalam
halal pharmaceuticals in, 410–411
TIFAs with, 2–3
BTA. See Bilateral Trade Agreement
Bush, George W., 2–3
Cambodia
IPRs in, 238
patent law in, xxii, 42
pharmaceutical production in, 18
TIFAs with, 2–3
Canada
Bolar exception in, 230–231
CETA and, 179
INDEX

competition law in, 301–302
Eli Lilly v Government of Canada, 78, 208–211
FTAs with Korea, 301–302
IPRs in, 369–370
ISDS system in, 203, 208–211
patentability in, 116–117
royalty rates in, 400–401
TRIPS Agreement and, 165
Canada (Commissioner of Patents) v Harvard College, 116–117
Canada-EU Comprehensive Economic and Trade Agreement (CETA), 179
Canadian Intellectual Property Office (CIPO), 370
cancer
access to medicines for, 404
in Asian populations, 8
CETA. See Canada-EU Comprehensive Economic and Trade Agreement
China. See also Association of Southeast Asian Nations
Antimonopoly Law in, 322–323
APIs in, 17
biotechnology patents in, 125
chronic disease in, 8
competition law in, 322–323
compulsory licensing in, 249–251
corruption issues in, 88–89
drug price controls in, 90–91
essential facilities, 322–323
FTAs in, 167–168
IPRs in, 322–323
new and secondary uses of drug compounds in, 135
non-working patents in, 249–251
patentability in, 125
pharmaceutical production in, 19
price caps in, for drugs and medicines, 420
procurement agreements in, 89–90
in WTO, 1
Chinese Taipei, 52, 256–257
chronic disease
in Asia, 7–8
in China, 8
CIPO. See Canadian Intellectual Property Office
civil society, access to medicine influenced by, 66
Coartem, 356
coherence, IPRs, trade, investment, innovation, public health and, 339
Common Market for Eastern and Southern Africa (COMESA) investment agreement, 271–273
communicable diseases, 6–7. See also Hepatitis C, HIV/AIDS
competition, within pharmaceutical industry, 62–64
competition law
access to medicine and, xxii
ARV drugs and, 299
AstraZeneca v Commission and, 295–296
in Australia, 300–301
in Canada, 301–302
in China, 322–323
essential facilities doctrine and, 303–305, 316–318, 333
in EU, 294–296
FTAs and, 306–307
FTC v Actavis and, 291–293
generic drugs and, 290
in Hong Kong, 323–324
in India, 324–325, 328–329
IPRs and, 286–289
in Japan, 324
in Lao PDR, 307–308
in Malaysia, 308–309
objectives of, 286–287
patent law and, 285
pay-for-delay agreements and, 285
pharmaceutical industry and, in Asia, 306–334
anticompetitive conduct and, 326–330
for ASEAN, 307–316, 325–326
compulsory licensing and, 326–330
competition law (cont.)
  patent linkage and, 331–332
  in the Philippines, 308
  refusal of licenses for patents and,
    302–303
  reverse-payment settlement agreements and, 285
  in Singapore, 309–316, 318
  in South Africa, 298–300
  in Thailand, 320
  in U.S., 289–294, 316
  in Vietnam, 321–322
compulsory licensing
  in Asia, 244, 254–260, 396–397
  in Bayer Corporation v NATCO Pharma Ltd., 246–248
  in Brazil, 245–246
  in China, 249–251
  to combat anti-competitive conduct, 259–260
  in COMESA investment agreement, 271–273
  in EU, 251
  for FTAs, 243–252
  government use, 396–397, 402–403
  in India, 246–249, 255, 327, 400
  in Indonesia, 255, 399–400
  in Malaysia, 255
  national provisions for, 244
  non-working of patents and, 244–252
  under Paris Convention, 243
  for pharmaceutical patents, 60
  in Singapore, 256–257, 312, 327, 329, 330–331
  in Taiwan, 255
  in Thailand, 62, 255, 257–259, 399–400
  under TRIPS, 60, 243–252, 402–403
constitutional rights to health in Asia, 38–41
consumers, in pharmaceutical industry, 62–64
copyrights. See also intellectual property rights
data sharing and, 357–358
societal benefits of, 357–358
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>through public funds, 365–366 developing countries</td>
<td></td>
</tr>
<tr>
<td>patents in, 104–105</td>
<td></td>
</tr>
<tr>
<td>tiered pricing systems in, for drugs and medicines, 385–387</td>
<td></td>
</tr>
<tr>
<td><em>Diamond v Chakrabarty</em>, 110</td>
<td></td>
</tr>
<tr>
<td>differential pricing, 377–378. See also tiered pricing, for drugs and medicines</td>
<td></td>
</tr>
<tr>
<td>disease. See chronic disease; communicable diseases</td>
<td></td>
</tr>
<tr>
<td>dispute resolution, 387</td>
<td></td>
</tr>
<tr>
<td>Doctors Without Borders. See Medicins Sans Frontières</td>
<td></td>
</tr>
<tr>
<td>Doha Declaration, 256–257, 338</td>
<td></td>
</tr>
<tr>
<td>domestic healthcare systems</td>
<td></td>
</tr>
<tr>
<td>access to medicine in, 38–41</td>
<td></td>
</tr>
<tr>
<td>ASEAN and, 38–41</td>
<td></td>
</tr>
<tr>
<td>Drug Price Competition and Patent Term Restoration Act, 291</td>
<td></td>
</tr>
<tr>
<td>drug research programmes, 366</td>
<td></td>
</tr>
<tr>
<td>drugs and medicines. See also approval systems, for drugs and medicines; generic drugs and medicines; medicines, in Asia; pricing, for drugs and medicines</td>
<td></td>
</tr>
<tr>
<td>biologics, 405–408</td>
<td></td>
</tr>
<tr>
<td>biosimilar products, 405–408</td>
<td></td>
</tr>
<tr>
<td>data sharing for access to medicine through, 354–358</td>
<td></td>
</tr>
<tr>
<td>copyrights and, 357–358</td>
<td></td>
</tr>
<tr>
<td>in EU, 362–365</td>
<td></td>
</tr>
<tr>
<td>new paradigm shifts for, 359–361</td>
<td></td>
</tr>
<tr>
<td>NITD and, 356</td>
<td></td>
</tr>
<tr>
<td>through open source systems, 358–359, 361</td>
<td></td>
</tr>
<tr>
<td>in pharmaceutical industry, 354–358</td>
<td></td>
</tr>
<tr>
<td>through public funds, 365–366 for Hepatitis C, pricing strategies for, 379–381</td>
<td></td>
</tr>
<tr>
<td>herbal, 409</td>
<td></td>
</tr>
<tr>
<td>new and secondary uses for biotechnology patents for, 127–137</td>
<td></td>
</tr>
<tr>
<td>in China, 135</td>
<td></td>
</tr>
<tr>
<td>in FTAs, 174–176</td>
<td></td>
</tr>
<tr>
<td>in India, 129–134</td>
<td></td>
</tr>
<tr>
<td>patentability of, 127–137</td>
<td></td>
</tr>
<tr>
<td>in Singapore, 135–137</td>
<td></td>
</tr>
<tr>
<td>in Thailand, 134–135</td>
<td></td>
</tr>
<tr>
<td>parallel imports of, 159–162</td>
<td></td>
</tr>
<tr>
<td>EBD. See Economic Development Board</td>
<td></td>
</tr>
<tr>
<td>economic development, globalization as influence on, 46–48</td>
<td></td>
</tr>
<tr>
<td>Economic Development Board (EBD), 350</td>
<td></td>
</tr>
<tr>
<td>economic reforms</td>
<td></td>
</tr>
<tr>
<td>in Asia, 41–44</td>
<td></td>
</tr>
<tr>
<td>in Myanmar, 2</td>
<td></td>
</tr>
<tr>
<td>economic treaties. See multilateral trade and treaties; treaties, economic</td>
<td></td>
</tr>
<tr>
<td>Egypt, pricing for drugs and medicines in, 379–381</td>
<td></td>
</tr>
<tr>
<td><em>Eli Lilly v Government of Canada</em>, 78, 208–211</td>
<td></td>
</tr>
<tr>
<td>EMA. See European Medicines Agency</td>
<td></td>
</tr>
<tr>
<td>EML. See Essential Medicines List</td>
<td></td>
</tr>
<tr>
<td>essential facilities doctrine, 303–305, 316–317</td>
<td></td>
</tr>
<tr>
<td>China, 305</td>
<td></td>
</tr>
<tr>
<td>competition law and, 317–318, 333</td>
<td></td>
</tr>
<tr>
<td>refusals to license, incipient linkages, 303–305</td>
<td></td>
</tr>
<tr>
<td>Essential Medicines List (EML), 11, 28</td>
<td></td>
</tr>
<tr>
<td>EU. See European Union</td>
<td></td>
</tr>
<tr>
<td>European Medicines Agency (EMA), 390–391</td>
<td></td>
</tr>
<tr>
<td>European Union (EU) AstraZeneca v Commission in, 295–296</td>
<td></td>
</tr>
<tr>
<td>Bolar exception in, 233</td>
<td></td>
</tr>
<tr>
<td>CETA and, 179</td>
<td></td>
</tr>
<tr>
<td>clinical data sharing scheme, 362–365</td>
<td></td>
</tr>
<tr>
<td>competition law in, 294–296</td>
<td></td>
</tr>
<tr>
<td>compulsory licensing in, 251</td>
<td></td>
</tr>
<tr>
<td>data exclusivity protection in, 188</td>
<td></td>
</tr>
<tr>
<td>data sharing in, 362–365</td>
<td></td>
</tr>
<tr>
<td>drug research programmes in, 366</td>
<td></td>
</tr>
<tr>
<td>EUSFTA, 184–186</td>
<td></td>
</tr>
<tr>
<td>FTAs and, 173</td>
<td></td>
</tr>
<tr>
<td>European Union (EU) (cont.)</td>
<td>INDEX</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>HiAP approach in, 374–376</td>
<td>formulary systems, in FTAs, 182–186</td>
</tr>
<tr>
<td>IMI, 348</td>
<td>free trade agreements (FTAs). See also</td>
</tr>
<tr>
<td>incentives for innovation in, 343–344</td>
<td>General Agreement on Trade</td>
</tr>
<tr>
<td>non-working patents in, 251</td>
<td>and Tariffs</td>
</tr>
<tr>
<td>patentability in, 111</td>
<td>anti-competition provisions in, 287</td>
</tr>
<tr>
<td>pay-for-delay agreements in, 296</td>
<td>ASEAN and, 2–3</td>
</tr>
<tr>
<td>increased competition law enforcement and, 294–296</td>
<td>data exclusivity protections in, 188–191</td>
</tr>
<tr>
<td>R&amp;D in, collaborations in, 348</td>
<td>patentability provisions for, 173–174</td>
</tr>
<tr>
<td>tiered pricing systems in, 378, 385–387</td>
<td>Asian approach to, xxi</td>
</tr>
<tr>
<td>TRIPS Agreement disputes, 165–166</td>
<td>BIPA, 206</td>
</tr>
<tr>
<td>EU-Singapore Free Trade Agreement (EUSFTA), 184–186</td>
<td>in China, 167–168</td>
</tr>
<tr>
<td>data exclusivity protection in, 196–197</td>
<td>competition law and, 306–307</td>
</tr>
<tr>
<td>evergreening approach in FTAs, 168, 240–241</td>
<td>compulsory licensing for, 243–252</td>
</tr>
<tr>
<td>to patents, 127</td>
<td>data exclusivity provisions in, 186–197, 260–263</td>
</tr>
<tr>
<td>exception provisions, in trade treaties in Asian regions, 226</td>
<td>dispute resolution provisions in, 387</td>
</tr>
<tr>
<td>in FTAs, xix, 221–223, 241–242</td>
<td>ethical business practices and, 215</td>
</tr>
<tr>
<td>in future treaties, 279–280</td>
<td>between EU and India, 173</td>
</tr>
<tr>
<td>General Saving of National Law, 241–242</td>
<td>EUSFTA, 184–186</td>
</tr>
<tr>
<td>for IPRs, 228–229</td>
<td>exception provisions in, xix, 221–223, 241–242</td>
</tr>
<tr>
<td>MFN treatment to, 266</td>
<td>exhaustion of rights in, 242</td>
</tr>
<tr>
<td>non-violation provisions for, 266–267</td>
<td>foreign policy measures in, 274–275</td>
</tr>
<tr>
<td>safe harbours provisions, 225–227</td>
<td>GATT and, 168–169</td>
</tr>
<tr>
<td>security exceptions, 273–274</td>
<td>General Saving of National Law exceptions in, 241–242</td>
</tr>
<tr>
<td>in TRIPS Agreement, 228–238</td>
<td>government policy-making as influence on, 429–430</td>
</tr>
<tr>
<td>in USSFTA, 226–227</td>
<td>health provisions, 23</td>
</tr>
<tr>
<td>exhaustion of rights, in FTAs, 242</td>
<td>impairment of, 266</td>
</tr>
<tr>
<td>expropriation in investment treaties, 268–273</td>
<td>India and, 3</td>
</tr>
<tr>
<td>in ISDS systems, 206–207</td>
<td>investment factors in, 23</td>
</tr>
<tr>
<td>external reference pricing, 382–383</td>
<td>investment interests as part of, 169–172</td>
</tr>
<tr>
<td>Fair and equitable treatment, ISDS system and, 204–206</td>
<td>investment treaties and, 268–273</td>
</tr>
<tr>
<td>First Currency Choice Pte Lyd v Main-Line Corporate Holdings Ltd, 70–71</td>
<td>in Israel, 191–192</td>
</tr>
<tr>
<td>in ISDS systems, 206–207</td>
<td>between Korea and Canada, 369–370</td>
</tr>
<tr>
<td>national formulary systems and, 182–186</td>
<td>Malaysia and, 171</td>
</tr>
<tr>
<td>MFN basis in, 219</td>
<td>negotiation options for, 280–281</td>
</tr>
<tr>
<td>NAFTA, 143, 186–187, 208–211</td>
<td>non-violation provisions for, 266–267</td>
</tr>
<tr>
<td>evergreening approach in, 242–243</td>
<td></td>
</tr>
<tr>
<td>in ISDS systems, 206–207</td>
<td></td>
</tr>
</tbody>
</table>
new and secondary uses of drug compounds in, 174–176
nullification of, 266
objectives in, 227–228
parallel imports in, limitations of, 180–181
patent bargain and, 71–77
patent linkage provisions in, 197–200, 262–263
patent opposition limitations in, 180
patent term extensions in, 176–179
patentability as aspect of, 172–176, 238–242
public health and, 169–172, 264–265, 371–373
regulatory provisions in, 214–215
reimbursement systems and, 182–186
renewal of patents under, 180
revocation of patents under, 180
scope of, 168–169
security exceptions in, 273–274
TPP and, 171–172
trade factors in, 23
trade interests as part of, 169–172
treaty protections for, 80
TRIPS-plus provisions, 219, 220–221
Free Trade Area of the Asia Pacific (FTAAP), 436–438
free-riding, 82
FTAAP. See Free Trade Area of the Asia Pacific
FTAs. See Free Trade Agreements
FCT v Actavis, 291–293
funding. See also health funds and prizes
for access to medicine, models for, 348–352
for data sharing, 365–366
Global Funds for AIDS, Tuberculosis and Malaria, 339
IFAD, 8
MAF, 13–15
SWFs, 350–352
General Agreement on Trade and Tariffs (GATT), 168–169, 212
exception provisions in, 221–223
negotiation options for, 280–281
non-violation provisions in, 266–267
General Saving of National Law exceptions, 241–242
Generic Drugs Act, 39–40
generic drugs and medicines, 16
Bolar exception and, 59, 229–238
competition law and, 290
counterfeit pharmaceuticals compared to, 98–99
ISDS systems and, 211
legal and policy constructs for, 102
substitution policies for, 95
genomes, gene sequences and BRCA, 109
patentability of, 109
GIIN. See Global Impact Investing Network
Gilead Sciences, 379–381
Glaxo Wellcome (Pty) Ltd & Others v National Association of Pharmaceutical Wholesalers & Others, 298–300
GlaxoSmithKline, 50
Global Funds for AIDS, Tuberculosis and Malaria, 339
Global Impact Investing Network (GIIN), 348
globalization
Asia influenced by, 1–3
economic development influenced by, 46–48
public health dimensions of, 46–56
good manufacturing practices (GMPs), 18
Goods & Services Tax (GST), 85–88
GSPOA. See Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property
GST. See Goods & Services Tax
INDEX

halal pharmaceuticals, 410–411
Hatch-Waxman amendments, 193.
See also Drug Price
Competition and Patent
Term Restoration Act
Hazel Tau and Others vs
GlaxoSmithKline and
Boehringer Ingelheim, 299
health care costs. See also health
expenditures, national
in Asia, 3, 12
containment of, access to medicine
influenced by, 65
out-of-pocket, 9
health expenditures, national
for pharmaceutical expenses,
9–11
in Singapore, 11–16
throughout Asia, 9–16
health funds and prizes, 339
Medical Innovation Prize Fund
Act, 340
Health in All Policies (HiAP) approach,
374–376
Health Sciences Authority (HSA),
193, 199
Health Technology Assessment (HTA),
376–377
healthcare systems
globalization as influence on,
46–56
in Singapore, public financing of,
13–15
social policy strategies for, 26–27
Hepatitis C
in Asia, 7
drugs and medicine for, pricing
strategies for, 379–381
herbal medicines, 409
HiAP approach. See Health in All
Policies approach
HIV/AIDS
ASEAN integration strategies,
425–426
in Asia, 6–7
Global Funds for AIDS, Tuberculosis
and Malaria, 339
pricing for drugs for, 381
Hong Kong
competition law in, 323–324
procurement agreements in, 89–90
HSA. See Health Sciences Authority
HTA. See Health Technology
Assessment
Human Genome Sciences Inc v Eli Lilly
Company, 69–70, 115, 284
IFAD. See International Fund for
Agricultural Development
IMI. See Innovative Medicines
Initiative
incentives, for innovation
for access to medicine, state’s role in,
67–68, 342–344
in EU, 343–344
Patents for Humanity programme,
343–344
in U.S., 343–344
India. See also Association of Southeast
Asian Nations
APIs in, 17
Bayer Corporation v NATCO
Pharma Ltd. in, 246–248
biotechnology in, 125–126
BIPA in, 206, 278–279
competition law in, 324–325,
328–329
compulsory licensing in, 246–249,
255, 327, 400
draft model investment treaty, 203,
206, 278–279
drug price controls in, 91–92
FTAs and, 3, 173
halal pharmaceuticals in, 410–411
IPRs in, 236
new and secondary uses of drug
compounds in, 129–134
non-profit organizations in, 66
non-working of patents in, 246–249
Novartis AG v Union of India,
129–134
open source systems, 361
patent law in, 43
patentability in, 125–126, 241
pricing for drugs and medicines
in, 383
INDEX

procurement agreements in, 89–90
TRIPS Agreement disputes, 165–166
Indonesia
biotechnology patents in, 124
compulsory licensing in, 255, 399–400
drug price controls in, 93
IPRs in, 237–238
patentability in, 124
pharmaceutical production in, 18
procurement agreements in, 89–90
TIFAs with, 2–3
innovation, innovators and access to medicine and, 64–65, 339
cohesion strategies for, access to medicines and, 339
C-Path Initiative, 348
free-riding on, 82
IMI and, 348
incentive theory and, 67–68, 342–344
interests of, 64–65
patent bargain and, 72, 79–80
in pharmaceutical industry, 51–55, 62–64
policy development for, 283–286
PPPs for, 344–348
in Singapore, 345–347
whole-of-government approach to, 373–376
innovation mercantilism, 82
Innovative Medicines Initiative (IMI), 348
Intellectual Property Office of Singapore (IPOS), 118–123
patentability, 118–123
public morals, 121
intellectual property rights (IPRs). See also data exclusivity protection, for patents access to medicines and, 338–339
ASEAN and, strategies for, 36, 43–44
in Asia, 41–44
in Cambodia, 238
in China, 369–370
in India, 238
in Indonesia, 237–238
ISDS systems and, 201–212
in Japan, 304
in Korea, 369–370
in Myanmar, 43
objectives of, 286–287
in the Philippines, 237
protectionist agenda for, in developed countries, 81, 82
reform strategies for, 301
shifts in, xvii
in Singapore, 118–123, 235–236, 310–311
in Thailand, 235
in TRIPS, exceptions to, 228–229
TRIPS and, xvii–xviii, 58–61
in U.S., 220–221
in Vietnam, 235
International Fund for Agricultural Development (IFAD), 8
investment treaties
COMESA investment agreement, 271–273
exception provisions in, relevant to health, 268–273
expropriation provisions in, relevant to health, 268–273
FTAs and, 268–273
investor-State dispute settlement (ISDS) system, 26
ASEAN and, claims against, 212, 213
in Asia, 202–203
in Australia, 203, 278
BIPA and, 206
in Canada, 203, 208–211
criticisms of, 211
damage sums through, 211–212
Eli Lilly v Government of Canada and, 208–211
expropriation issues in, 206–207
FET and, 204–206
generic medicines and, 211
investment provisions in, 204–206
IPRs and, 201–212
investor-State dispute (cont.)
in Latin America, 201–202
legal risks and concerns in, 201–214
NAFTA and, 208–211
patent bargain and, 212–214
pharmaceutical patents and, 208–211
scope of, 201–212
security exceptions in, 273
TTIP and, 216–217
IPOS. See Intellectual Property Office of Singapore
IPRs. See intellectual property rights
ISDS. See investor-State dispute settlement system
Israel
data exclusivity protection in, 191–192
FTAs in, 191–192
Japan
APIs in, 17
competition law in, 324
IPRs in, 304
JSEPA, 227
procurement agreements in, 89–90
refusal of licenses for patents in, 304
Japan-Singapore Economic Partnership Agreement (JSEPA), 227
KFTC. See Korean Fair Trade Commission
Korea. See also Association of Southeast Asian Nations
APIs in, 17
biotechnology in, 126–127
drug price controls in, 92–93
FTAs with Canada, 369–370
IPRs in, 369–370
KFTC v GSK/Dong-A, 297–298
KORUS FTA, 182–183, 197–198, 226–227
non-profit organizations in, 66
Ombudsman, 387
patentability in, 126–127
pay-for-delay agreements in, 297–298
procurement agreements in, 89–90
Korean Fair Trade Commission (KFTC), 297–298
Korea-U.S. Free Trade Agreement (KORUS FTA), 182–183
exception provisions in, 226–227
formulary, 182–183
patent linkage provisions in, 197–198
Lao PDR
competition law in, 307–308
compliance with TRIPS, 42
patent law in, xxii–xxiii
pharmaceutical production in, 18
poverty in, 9
Latin America, ISDS systems in, 201–202
law
access to medicine and, 26–27
scientific advances in medicine and, 26–27
legal and policy constructs. See also patent law
ASEAN and, 103
for generic medicines, 102
for patentability, 104–105
for trade and investment in medicines, 101–102
licensing. See compulsory licensing;
public use licensing; refusal of licenses; voluntary licensing
life expectancy, in Asia, 5
Lincoln, Abraham, 68
local medical traditions. See traditional medicines
MAF. See Medication Assistance Fund
malaria in Asia, 7
Global Funds for AIDS, Tuberculosis and Malaria, 339
Mozambique Malaria Performance Bond, 350
Malaysia
AstraZeneca AB v Ranbaxy (Malaysia) Sdn Bhd in, 143
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>biotechnology patents</td>
<td>123–124</td>
</tr>
<tr>
<td>competition law</td>
<td>308–309</td>
</tr>
<tr>
<td>compulsory licensing</td>
<td>255</td>
</tr>
<tr>
<td>data exclusivity protection</td>
<td>146–154</td>
</tr>
<tr>
<td>FTAs and</td>
<td>171</td>
</tr>
<tr>
<td>GST in</td>
<td>85–88</td>
</tr>
<tr>
<td>halal pharmaceuticals</td>
<td>410–411</td>
</tr>
<tr>
<td>patent linkage</td>
<td>141</td>
</tr>
<tr>
<td>patentability</td>
<td>123–124</td>
</tr>
<tr>
<td>pharmaceutical industry</td>
<td>85–88</td>
</tr>
<tr>
<td>pharmaceutical production</td>
<td>18, 20–21</td>
</tr>
<tr>
<td>procurement agreements</td>
<td>89–90</td>
</tr>
<tr>
<td>TIFAs with</td>
<td>2–3</td>
</tr>
<tr>
<td>Mandelson, Peter</td>
<td>258</td>
</tr>
<tr>
<td>Mayo Collaborative Services and Mayo Medical Laboratories et al v Prometheus Inc</td>
<td>110</td>
</tr>
<tr>
<td>Medical Innovation Prize Fund</td>
<td>340</td>
</tr>
<tr>
<td>Medication Assistance Fund (MAF),</td>
<td>13–15</td>
</tr>
<tr>
<td>medicines, in Asia</td>
<td></td>
</tr>
<tr>
<td>Meds, Florida</td>
<td></td>
</tr>
<tr>
<td>Mininshu Losha</td>
<td></td>
</tr>
<tr>
<td>Mo, Peter</td>
<td></td>
</tr>
<tr>
<td>Murray, Kali</td>
<td>68</td>
</tr>
<tr>
<td>Myanmar</td>
<td></td>
</tr>
<tr>
<td>MFN</td>
<td>219, 266</td>
</tr>
<tr>
<td>Mozambique Malaria Performance Bond</td>
<td>350</td>
</tr>
<tr>
<td>MPP</td>
<td></td>
</tr>
<tr>
<td>MTI</td>
<td></td>
</tr>
<tr>
<td>multilateral trade and treaties</td>
<td></td>
</tr>
<tr>
<td>access to medicines influenced by</td>
<td>389–404</td>
</tr>
<tr>
<td>for public health</td>
<td>366–367</td>
</tr>
<tr>
<td>for R&amp;D</td>
<td>366–367</td>
</tr>
<tr>
<td>Murray, Kali</td>
<td>68</td>
</tr>
<tr>
<td>NAFTA</td>
<td></td>
</tr>
<tr>
<td>National Essential Medicines System</td>
<td>11</td>
</tr>
<tr>
<td>national health expenditures</td>
<td></td>
</tr>
<tr>
<td>NCEs, See new chemical entities</td>
<td></td>
</tr>
<tr>
<td>neglected drugs</td>
<td>67–68</td>
</tr>
<tr>
<td>Neglected Tropical Disease</td>
<td>7</td>
</tr>
<tr>
<td>NEMS, See National Essential Medicines System</td>
<td></td>
</tr>
<tr>
<td>the Netherlands, TRIPS Agreement</td>
<td></td>
</tr>
<tr>
<td>new chemical entities</td>
<td>61</td>
</tr>
<tr>
<td>NITD, See Novartis Institute for Tropical Diseases</td>
<td></td>
</tr>
<tr>
<td>non-FTA mechanisms, international patent law</td>
<td>172</td>
</tr>
<tr>
<td>migrant workers, public health</td>
<td>428</td>
</tr>
<tr>
<td>Millenium Development Goals</td>
<td>(MDGs), 30</td>
</tr>
<tr>
<td>Minister for Trade and Industry (MTI)</td>
<td>169–170</td>
</tr>
<tr>
<td>Mongolia, procurement agreements</td>
<td>89–90</td>
</tr>
<tr>
<td>most-favoured nations</td>
<td>219, 266</td>
</tr>
<tr>
<td>Mozambique Malaria Performance Bond</td>
<td>350</td>
</tr>
<tr>
<td>MPP</td>
<td></td>
</tr>
<tr>
<td>MTI</td>
<td></td>
</tr>
<tr>
<td>multilateral trade and treaties</td>
<td></td>
</tr>
<tr>
<td>specific treaties</td>
<td></td>
</tr>
<tr>
<td>access to medicines</td>
<td>389–404</td>
</tr>
<tr>
<td>for public health</td>
<td>366–367</td>
</tr>
<tr>
<td>for R&amp;D</td>
<td>366–367</td>
</tr>
<tr>
<td>Murray, Kali</td>
<td>68</td>
</tr>
<tr>
<td>Myanmar</td>
<td></td>
</tr>
<tr>
<td>MFN</td>
<td></td>
</tr>
<tr>
<td>Mozambique Malaria Performance Bond</td>
<td>350</td>
</tr>
<tr>
<td>MPP</td>
<td></td>
</tr>
<tr>
<td>MTI</td>
<td></td>
</tr>
<tr>
<td>multilateral trade and treaties</td>
<td></td>
</tr>
<tr>
<td>access to medicines</td>
<td>389–404</td>
</tr>
<tr>
<td>for public health</td>
<td>366–367</td>
</tr>
<tr>
<td>for R&amp;D</td>
<td>366–367</td>
</tr>
<tr>
<td>Murray, Kali</td>
<td>68</td>
</tr>
<tr>
<td>NAFTA</td>
<td></td>
</tr>
<tr>
<td>National Essential Medicines System</td>
<td>11</td>
</tr>
<tr>
<td>national health expenditures</td>
<td></td>
</tr>
<tr>
<td>NCEs, See new chemical entities</td>
<td></td>
</tr>
<tr>
<td>neglected drugs</td>
<td>67–68</td>
</tr>
<tr>
<td>Neglected Tropical Disease</td>
<td>7</td>
</tr>
<tr>
<td>NEMS, See National Essential Medicines System</td>
<td></td>
</tr>
<tr>
<td>the Netherlands, TRIPS Agreement</td>
<td></td>
</tr>
<tr>
<td>new chemical entities</td>
<td>61</td>
</tr>
<tr>
<td>NITD, See Novartis Institute for Tropical Diseases</td>
<td></td>
</tr>
<tr>
<td>non-FTA mechanisms, international patent law</td>
<td>172</td>
</tr>
</tbody>
</table>
non-profit organizations
  access to medicine influenced by, 66
  in India, 66
  in Korea, 66
  in Thailand, 66
non-violation provisions, 266–267
non-working patents
  in Brazil, 245–246
  in China, 249–251
  compulsory licensing and, 244–252
  in EU, 251
  in India, 246–249
North American Free Trade Agreement (NAFTFA)
  data exclusivity protections under, 143, 186–187
  ISDS systems and, 208–211
Novartis, access to medicines initiative
  Novartis AG v Union of India, 129–134
Novartis Institute for Tropical Diseases (NITD), 356
Occidental v Ecuador, 211–212
Open Source Drug Discovery (OSDD) Programme, 361
open source systems, 358–359, 361
organizations, international. See also World Health Organization; World Trade Organisation
  role in access to medicine, 27–29
OSDD Programme. See Open Source Drug Discovery Programme
Ottawa Charter for Health
  Promotion, 30
out-of-pocket health care costs, in Asia, 9
“Paragraph 6” mechanism, WTO, 250, 273, 327
parallel imports
  of drugs and medicines, 159–162
  in FTAs, 180–181
  international exhaustion and, ASEAN, 161–162
  in Singapore, 180–181
tiered pricing and, EU system, 385–387
Paris Convention, 243
patent bargain, 68–72, 77–78
  commercial practices and, 80
  FTAs and, 71–77
  innovation and, 72
  innovator-incentive approach in, 79–80
ISDS system and, 212–214
  negotiation trade-offs as part of, 79
  rewards theory and, 72
  social contract theory and, 72
  state interests in, 79
  “treatified”, 71–77
  treaty protections and, 80
  TRIPS Agreement and, 71–77, 162–163
WTO members and, 74–76
Patent Cooperation Treaty, 31
patent law. See also intellectual property rights
  access to medicines and, 68–72, 418–420
  in Australia, 56–57
  Brenner v Manson and, 70
  in Cambodia, xxii, 42
  competition law and, 285
  Eli Lilly v Government of Canada and, 78
  in First Currency Choice Pte Lyd v Main-Line Corporate Holdings Ltd, 70–71
government reviews on, 56
  in Human Genome Sciences Inc v Eli Lilly Company, 69–70
  in India, 43
  key elements of, 103–117
  KFTC and, 297–298
  in Lao PDR, xxii
  in Myanmar, xxii
  non-FTA mechanisms and, 172
  quid pro quo status in, 69
  in Teva Canada v Pfizer Canada, 70
  in Thailand, 62
  under TRIPS, 25–26, 58–61
patent linkage
  approval systems and, 137–143
  for biotechnology patents, 137–143
  in FTAs, 197–200, 262–263
for generic competitors, 141–143
judicial decisions of interest on, 141–143
in KORUS FTA, 197–198
in Malaysia, 141
patentability and, 137–143
in Singapore, 141–143
Medicines Act, 141–143
patent term extensions, 156–158
in ASEAN countries, 157, 161–162
in Asian region, 157–158, 161–162
in FTAs, 176–179
in USSFTA, 177–179
patentability
access to medicine and, 418–420
approval systems for, 137–143
in Asia, 108–109, 117–127
in Australia, 111–113
of biotechnology, 106–117
of BRCA genes, 109
in Canada, 116–117
in China, 125
data exclusivity protections and, 143–156
defined, 104–105
divergent approaches to, 117–127
in EU, 111
evergreening approach to, 127
FTAs and, 172–176, 238–242
as a gateway, 104
of genes and gene sequences, 109
in India, 125–126, 241
in Indonesia, 124
in Korea, 126–127
in Malaysia, 123–124
of new and secondary uses of compounds, 127–137
patent linkage as factor in, 137–143
in the Philippines, 124
regulatory issues for, 107–108
in Singapore, 118–123
in Thailand, 124
TRIPS Agreement and, 238–242
in U.K., 108, 115
in U.S., 108, 110–111
USSFTA and, 173–174
in Vietnam, 125
patents, pharmaceutical, 66–80. See also biotechnology patents; competition law; data exclusivity protection, for patents; non-working patents
access to medicines and, 68–72
Brenner v Manson and, 70
costal practices for, 80
compulsory licensing for, 60
in developing countries, 104–105
Eli Lilly v Government of Canada and, 78
evergreening approach to, 127
exhaustion of, 161–162
First Currency Choice Pte Lyd v Main-Line Corporate Holdings Ltd and, 70–71
under FTAs, renewal and revocation of, 180
in Human Genome Sciences Inc v Eli Lilly Company, 69–70
innovative-incentive approach to, 67–68
international commitments, 57–58
ISDS system and, 208–211
NCEs and, 61
patentability, 104–105
quid pro quo status for, 69
state interests in, 65
submarine, 105
Teva Canada v Pfizer Canada and, 70
treaty protections and, 80
under TRIPS Agreement, 57–61
Patents Act, 180–181
Patents for Humanity programme, 343–344
pay-for-delay agreements
in Asia, 297–298
in AstraZeneca v Commission, 295–296
competition law and, 285
in EU, 296
in Korea, 297–298
patent law and, 297–298
in U.S., 293–294
personalized medicines, 408
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMCPA. See Prescription Medicines Code of Practice Authority</td>
<td>413</td>
</tr>
<tr>
<td>populations</td>
<td>85–88</td>
</tr>
<tr>
<td>aging of, in Asia, 3, 4–6</td>
<td>88–90</td>
</tr>
<tr>
<td>estimated projections for, 5</td>
<td>90–94</td>
</tr>
<tr>
<td>poverty</td>
<td>91–92</td>
</tr>
<tr>
<td>populations</td>
<td>93</td>
</tr>
<tr>
<td>Lao PDR in, 9</td>
<td>96–98</td>
</tr>
<tr>
<td>PPPs. See public-private partnerships</td>
<td>336–337</td>
</tr>
<tr>
<td>Precision Medicine Initiative, 408</td>
<td></td>
</tr>
<tr>
<td>Prescription Medicines Code of Practice Authority (PMCPA)</td>
<td>413</td>
</tr>
<tr>
<td>pricing, for drugs and medicines, 17–18</td>
<td>336–337</td>
</tr>
<tr>
<td>in China, through price caps, 420</td>
<td></td>
</tr>
<tr>
<td>differential, 377–378</td>
<td>432–435</td>
</tr>
<tr>
<td>in Egypt, 379–381</td>
<td>444–447</td>
</tr>
<tr>
<td>external reference, 382–383</td>
<td>455</td>
</tr>
<tr>
<td>for Hepatitis C, 379–381</td>
<td></td>
</tr>
<tr>
<td>for HIV/AIDS, 381</td>
<td>455</td>
</tr>
<tr>
<td>in India, 383</td>
<td>455</td>
</tr>
<tr>
<td>negotiation strategies for, 379–381</td>
<td>455</td>
</tr>
<tr>
<td>for pharmaceutical industry, in Asia, 85–88</td>
<td>455</td>
</tr>
<tr>
<td>in China, 90–91</td>
<td>455</td>
</tr>
<tr>
<td>control systems in, 90–94</td>
<td>455</td>
</tr>
<tr>
<td>in India, 91–92</td>
<td>455</td>
</tr>
<tr>
<td>in Indonesia, 93</td>
<td>455</td>
</tr>
<tr>
<td>in Korea, 92–93</td>
<td>455</td>
</tr>
<tr>
<td>in Myanmar, 93</td>
<td>455</td>
</tr>
<tr>
<td>in the Philippines, 93–94</td>
<td>455</td>
</tr>
<tr>
<td>in Vietnam, 94</td>
<td>455</td>
</tr>
<tr>
<td>for sofosbuvir, 379–381</td>
<td>455</td>
</tr>
<tr>
<td>tiered, 377–387</td>
<td>455</td>
</tr>
<tr>
<td>demand-side concerns for, 384</td>
<td>455</td>
</tr>
<tr>
<td>for developing countries, 385–387</td>
<td></td>
</tr>
<tr>
<td>disincentives for, 382</td>
<td>455</td>
</tr>
<tr>
<td>in EU, 378, 385–387</td>
<td>455</td>
</tr>
<tr>
<td>for global pharmaceutical companies, 379</td>
<td>455</td>
</tr>
<tr>
<td>supply-side concerns for, 382–384</td>
<td></td>
</tr>
<tr>
<td>sustainable frameworks for, 381</td>
<td></td>
</tr>
<tr>
<td>procurement, corruption and, 88–90</td>
<td>455</td>
</tr>
<tr>
<td>415, 420–422</td>
<td>455</td>
</tr>
<tr>
<td>procurement agreements, 88–90</td>
<td>455</td>
</tr>
<tr>
<td>public health</td>
<td>455</td>
</tr>
<tr>
<td>ASEAN and, 427–428</td>
<td>455</td>
</tr>
<tr>
<td>in BRICS nations, 430–432</td>
<td>455</td>
</tr>
<tr>
<td>dispute resolution provisions for, 387</td>
<td>455</td>
</tr>
<tr>
<td>FTAs for, 169–172, 264–265, 371–373</td>
<td>455</td>
</tr>
<tr>
<td>health representatives in negotiation process, 370–371</td>
<td>455</td>
</tr>
<tr>
<td>HiAP approach to, 374–376</td>
<td>455</td>
</tr>
<tr>
<td>HTA for, 376–377</td>
<td>455</td>
</tr>
<tr>
<td>for migrant workers, 428</td>
<td>455</td>
</tr>
<tr>
<td>multilateral treaty for, 366–367</td>
<td></td>
</tr>
<tr>
<td>national agencies’ role in, 370–371</td>
<td></td>
</tr>
<tr>
<td>trade and investment treaty and, 368–369</td>
<td>455</td>
</tr>
<tr>
<td>treaty-based approaches to, 366–367</td>
<td></td>
</tr>
<tr>
<td>whole-of-government approach to, 373–376</td>
<td>455</td>
</tr>
<tr>
<td>Public Health Declaration, 252–254</td>
<td>455</td>
</tr>
<tr>
<td>public morals and patentability, 418–420</td>
<td>455</td>
</tr>
<tr>
<td>public use licensing, 396–397</td>
<td>455</td>
</tr>
<tr>
<td>public-private partnerships (PPPs), 336–337</td>
<td>455</td>
</tr>
<tr>
<td>C-Path Initiative, 348</td>
<td>455</td>
</tr>
<tr>
<td>IMI and, 348</td>
<td>455</td>
</tr>
<tr>
<td>for R&amp;D, for public health promotion, 344–348</td>
<td>455</td>
</tr>
<tr>
<td>RCEP. See Regional Comprehensive Economic Partnership</td>
<td>455</td>
</tr>
<tr>
<td>R&amp;D. See research and development</td>
<td>455</td>
</tr>
<tr>
<td>refusal of licenses, for patents, 302–305</td>
<td>455</td>
</tr>
<tr>
<td>competition law and, 302–303</td>
<td>455</td>
</tr>
<tr>
<td>essential facilities doctrine and, 303–305</td>
<td>455</td>
</tr>
<tr>
<td>in Japan, 304</td>
<td>455</td>
</tr>
<tr>
<td>Regional Comprehensive Economic Partnership (RCEP), 3</td>
<td>455</td>
</tr>
<tr>
<td>regional healthcare systems</td>
<td>455</td>
</tr>
<tr>
<td>access to medicine in, 32–41</td>
<td>455</td>
</tr>
<tr>
<td>ASEAN role in, 32–41</td>
<td>455</td>
</tr>
<tr>
<td>in Myanmar, 40–41</td>
<td>455</td>
</tr>
<tr>
<td>RCEP and, 3</td>
<td>455</td>
</tr>
<tr>
<td>in Thailand, 41</td>
<td>455</td>
</tr>
<tr>
<td>in Vietnam, 40</td>
<td>455</td>
</tr>
<tr>
<td>regional trade agreements (RTAs), 168–169</td>
<td>455</td>
</tr>
<tr>
<td>reimbursement systems, in FTAs, 182–186</td>
<td>455</td>
</tr>
<tr>
<td>research, new platform in, 432–435</td>
<td>455</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press  www.cambridge.org
Sri Lanka, procurement agreements in, 89–90
Standard Drug List (SDL), 13–15, 129
Straterra, 208
submarine patents, 105
Sustainable Development Goals (SDGs), 31, 35, 437
SWFs. See sovereign wealth funds
Taiwan (Chinese Taipei), compulsory licensing in, 255
tariffs, for pharmaceutical industry, in Asia, 83–84, 85
taxes
GST, in Malaysia and Singapore, 85–88
for pharmaceutical industry, in Asia, 85–88
Teva Canada v Pfizer Canada, 70
Thailand
APIs in, 17
ARV drugs in, 16
biotechnology patents in, 124
competition law in, 320
compulsory licensing in, 62, 255, 257–259, 399–400
halal pharmaceuticals in, 410–411
IPRs in, 235
new and secondary uses of drug compounds in, 134–135
non-profit organizations in, 66
patent law in, 62
patentability in, 124
pharmaceutical patent litigation in, 134–135
pharmaceutical production in, 18, 19–20
regional healthcare systems in, 41
TIFAs with, 2–3
tiered pricing, for drugs and medicines, 377–387
demand-side concerns for, 384
for developing countries, 385–387
disincentives for, 382
in EU, 378, 385–387
for global pharmaceutical companies, 379
supply-side concerns for, 382–384
sustainable frameworks for, 381
TIFA. See Trade and Investment Framework Agreement
TPP Agreement. See Trans-Pacific Partnership Agreement
trade and investment, in medicines
coherence strategies for, 339
FTAs for, 169–172
legal and policy constructs for, 101–102
negotiation options for, 280–281
for public health, 368–369
whole-of-government approach to, 373–376
Trade and Investment Framework Agreement (TIFA), 2–3
See also biotechnology patents; Bolar exception, in TRIPS; compulsory licensing; free trade agreements
access to medicine and, 24–26
anti-competitive conduct under, 259–260
Article 31, 60
Article 39, 260–263, 390–392
Asian approach to, xxii
balance of, interpretation of, 389–392
Brazil and, 165
in Canada, 165
compulsory licensing under, 243–252, 402–403
data exclusivity and, 260–263
EMA and, 390–391
EU and, trade disputes under, 165–166
extceptions to, 228–238
flexibilities under, 58–61, 238–266, 338–339
India and, dispute with EU, 165–166
international disputes, 165–167
IPRs and, xvii–xviii, 58–61
Lao PDR and, 42
Trade-Related Aspects (cont.)
least developed countries (LDCs) and, 41–44, 50, 76, 211–212, 381
legal obligations in, 164
NAFTA and, 143, 186–187
NCEs under, 61
negotiation options for, 280–281
the Netherlands and, 165
objectives of, 227–228
"Paragraph 6" mechanism, Article 31(f) waiver, 60, 252–254
parallel imports under, 159–162
patent bargain and, 71–77, 162–163
patent law and, 25–26
patentability under, 238–242
pharmaceutical industry and, 52–55, 58–61
pharmaceutical patents under, 57–58
principles of, 227–228
protectionist agenda in developed countries and, 81, 82
public debate over, 81–82
Public Health Declaration and, 252–254
royalty rates in, 394–404
treaty protections with, 80
TRIPS-plus provisions, FTAs, 219, 220–221
UN Human Rights Council and, 59
UNAIDS and, 59
undisclosed information, 57, 74, 144, 192, 234, 260–262, 305
UNDP and, 59
U.S. and, 165, 167
WHO and, 59
WTO and, xvii, 22–23, 164, 165–167
traditional medicines
access to medicine through, 408–409
in Asia, 21–22
Transatlantic Trade and Investment Partnership (TTIP), 216–217
Trans-Pacific Partnership (TPP) Agreement, 23
biologics in, 407–408

FTAs and, 171–172
treaties, economic. See also exception provisions, in trade treaties; free trade agreements; General Agreement on Trade and Tariffs; multilateral trade and treaties; Trade-Related Aspects of Intellectual Property Rights Agreement coherence among, 339
interpretation of language in, 275–277
negotiation strategies for, 277–281
for R&D, 366–377
safe harbours exceptions in, 225–227
WTO accession protocols in, 224–225
TRIPS Agreement. See Trade-Related Aspects of Intellectual Property Rights Agreement
TRIPS-plus. See free trade agreements
TTIP. See Transatlantic Trade and Investment Partnership
tuberculosis, in Asia, 7

U.K. See United Kingdom
UN Human Rights Council, 59
UNAIDS. See United Nations Programme on HIV/AIDS
undisclosed information, TRIPS Agreement, Article 39, 260–263
UNDP. See United Nations Development Programme
United Kingdom (U.K.)
Human Genome Sciences Inc v Eli Lilly Company in, 69–70, 115, 284
patentability in, 108, 115
United Nations Development Programme (UNDP), 59
United Nations Programme on HIV/AIDS (UNAIDS), 59
United States (U.S.)
BTA and, with Vietnam, 257
competition law in, 289–294, 316
C-Path Initiative in, 348
INDEX

- data exclusivity protection in, 187–188
- Drug Price Competition and Patent Term Restoration Act in, 291
- drug research programmes in, 366
- economic interest in Asia, 2–3
- Hatch-Waxman amendments in, 193
- incentives for innovation in, 343–344
- IPRs in, 220–221
- Medical Innovation Prize Fund Act in, 340
- patentability issues in, 108, 110–111
- Patents for Humanity programme in, 343–344
- pay-for-delay agreements in, 293–294
- Precision Medicine Initiative in, 408
- R&D in, collaborations in, 348
- TIFA and, 2–3
- TRIPS Agreement disputes and, 165, 167
- Universally Cheaper and Quality Medicines Act, 40, 155–156
- exception provisions in, 226–227
- patent linkage provisions in, 198–200, 262–263
- patent term extensions in, 177–179
- patentability provisions in, 173–174
- Vienna Convention on the Law of Treaties (VCLT), 231
- Vietnam
  - biotechnology patents in, 125
  - BTA and, with U.S., 257
- competition law in, 321–322
- corruption issues in, 88–89
- drug price controls in, 94
- IPRs in, 235
- patentability in, 125
- pharmaceutical production in, 18
- procurement agreements in, 89–90
- regional healthcare systems in, 40
- TIFAs with, 2–3
- voluntary licensing
  - access to medicine through, 340–342, 433
  - MPP, 339, 340–342, 411
- World Health Organization (WHO), 27–29
- EML and, 28
- GSPOA, 335–336
- HTA advocacy by, 376–377
- TRIPS and, 59
- World Intellectual Property Organization (WIPO), 59, 357, 360, 419, 432–435, 438
- World Trade Organisation (WTO)
  - accession protocol commitments, 224–225
  - Agreement on Pharmaceutical Products, 393–394
  - China in, 1
  - dispute settlement system, Asian use of, 2
  - disputes, TRIPS and, 22, 146, 164, 165–167, 245–246
  - patent bargain and, 74–76
  - Pharmaceutical Products Agreement for, 393–394
  - procurement agreements, 89–90
  - trilateral study with WHO and WIPO, 432–435
  - TRIPS Agreement and, xvii, 22–23, 164, 165–167
- Zyprexa, 208